Article Information
History
- September 14, 2021.
Article Versions
- Version 1 (September 12, 2021 - 01:26).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Peter Bergman, MD1,2,*,
- Ola Blennow, MD1,3,4,*,
- Lotta Hansson, MD5,6,*,
- Stephan Mielke, MD7,8,*,
- Piotr Nowak, MD1,9,10,*,
- Puran Chen, MD11,
- Gunnar Söderdahl, MD3,4,
- Anders Österborg, MD5,6,
- C. I. Edvard Smith, MD1,8,
- David Wullimann, MSc11,
- Jan Vesterbacka, MD1,
- Gustaf Lindgren, MD8,
- Lisa Blixt, MD5,6,
- Gustav Friman, MD3,4,
- Emilie Wahren-Borgström, MD1,
- Anna Nordlander, MD8,
- Angelica Cuapio Gomez, MD11,
- Mira Akber, MSc11,
- Davide Valentini, PhD8,
- Anna-Carin Norlin, MD1,
- Anders Thalme, MD1,
- Gordana Bogdanovic, MD12,
- Sandra Muschiol, PhD12,13,
- Peter Nilsson, PhD14,
- Sophia Hober, PhD14,
- Karin Loré, PhD15,
- Margaret Sällberg Chen, PhD16,
- Marcus Buggert, PhD11,
- Hans-Gustaf Ljunggren, MD11,
- Per Ljungman, MD8,17,
- Soo Aleman, MD1,9,#,
- the COVAXID-collaborator group (shown separately)
- 1Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- 2Department of Laboratory Medicine, Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden
- 3Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden
- 4Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- 5Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
- 6Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
- 7Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden
- 8Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden
- 9Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden
- 10Laboratory for Molecular Infection Medicine Sweden MIMS, Umeå University, Sweden
- 11Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden
- 12Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
- 13Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
- 14Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
- 15Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 16Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
- 17Department of Medicine Huddinge, Hematology, Karolinska Institutet, Stockholm
- ↵#Corresponding author:
Soo Aleman, Department of Infectious Diseases, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. E-mail: soo.aleman{at}ki.se Tel: +46 72 595 72 25.
↵* Equally shared first authorship in alphabetical order
Posted September 14, 2021.
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
